Every Form 4 that Trevi Therapeutics (TRVI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TRVI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRVI filings page.
Trevi Therapeutics director Edward T. Mathers received a new stock option grant covering 35,000 shares of common stock. The nonstatutory option has an exercise price of $13.45 per share and expires on June 2, 2036.
According to the terms, the option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders held after that date, as long as Mathers continues to serve as a director, employee, or consultant of Trevi Therapeutics.
Trevi Therapeutics director Dominick Colangelo received a new stock option grant. On the reported date, he was granted a nonstatutory option to buy 35,000 shares of Trevi Therapeutics common stock at an exercise price of $13.45 per share.
The option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders held after that date, as long as he continues to serve as a director, employee or consultant. Following this grant, he holds 35,000 stock options directly.
Trevi Therapeutics, Inc. director David P. Meeker received a grant of a nonstatutory stock option covering 35,000 shares of common stock. The option has an exercise price of $13.45 per share and expires on June 2, 2036.
The option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting held after that date, subject to his continued service as a director, employee or consultant. Following this grant, Meeker holds 35,000 derivative securities directly.
Trevi Therapeutics director Anne Vanlent received a grant of stock options covering 35,000 shares of common stock. The nonstatutory options have an exercise price of $13.45 per share and expire on June 2, 2036. All 35,000 underlying shares are scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual meeting of stockholders, as long as she continues serving as a director, employee or consultant. Following this award, her reported derivative holdings from this grant total 35,000 options, reflecting a routine compensation-related acquisition rather than an open-market purchase.
Trevi Therapeutics director Michael Thomas Heffernan received a grant of stock options covering 35,000 shares of common stock. The nonstatutory stock option has an exercise price of $13.45 per share and expires on June 2, 2036. The award was granted for his service as a director and will fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting, as long as he continues serving the company. Following this grant, he holds 35,000 options directly under this award.
Cassella James V reported acquisition or exercise transactions in this Form 4 filing.
Trevi Therapeutics, Inc. reported that Chief Development Officer James V. Cassella received a grant of stock options covering 215,000 shares of common stock on February 19, 2026. The options were granted at a price of $0.0000 per share as a compensation award.
The 215,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, and vesting depends on Cassella’s continued service with the company. Following this award, he holds stock options for 215,000 shares directly.
Trevi Therapeutics, Inc. reported that company officer Christopher Galletta received a grant of stock options covering 35,000 shares of common stock. The award was made on February 19, 2026 as a compensation-related acquisition, not an open-market purchase.
The 35,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, conditioned on Galletta’s continued service with the company. This filing simply records the new equity award and Galletta’s resulting direct ownership of these options.
Trevi Therapeutics, Inc. reported that its Chief Scientific Officer, Thomas Sciascia, received a grant of stock options covering 85,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase. According to the filing, these 85,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, and the vesting is conditioned on his continued service with the company.
Trevi Therapeutics, Inc. reported that President and CEO Jennifer L. Good received a grant of stock options covering 675,000 shares of common stock. The award was granted on February 19, 2026 at no cost on grant and represents a compensation-related acquisition, not an open-market purchase.
The 675,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, so long as she continues her service with the company. This structure ties the potential ownership benefit to her ongoing tenure over the multi-year vesting period.
Simon Farrell reported acquisition or exercise transactions in this Form 4 filing.
Trevi Therapeutics Chief Commercial Officer Simon Farrell received a grant of stock options covering 160,000 shares of common stock. The award was made on February 19, 2026 as an equity incentive.
The 160,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, conditioned on Farrell’s continued service with the company.
Trevi Therapeutics reported that its Chief Financial Officer, David C. Hastings, received a grant of stock options on January 8, 2026. The award covers 375,000 stock options to purchase common stock at an exercise price of $11.21 per share. According to the vesting schedule, 25% of the underlying 375,000 shares vest on January 8, 2027, with the remaining 75% vesting in equal monthly installments through January 8, 2030. After this grant, Hastings beneficially owns 375,000 derivative securities directly in the form of these options.